NHS Framework - Blood Disorders including Haemophilia A and B - July 2024
Estimated value
—
Awarded value
—
Suppliers
31
Lots
23
Published
11 Jun 2024
Description
Project Title: NHS National Framework Agreement for the supply of products for the treatment of Blood Disorders including Haemophilia A and B - July 2024<br/><br/>Offer reference number: CM/PHS/22/5661<br/><br/>Period of framework: 1 July 2024 to 30 April 2027 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 14 months.<br/><br/>Published By: Medicines Procurement and Supply Chain – NHS Medicines Value & Access, NHS England
Scope
- Reference
- CM/PHS/22/5661
- Commercial tool
- Standalone contract
- Contract dates
- 30 Jun 2024 to 30 Apr 2027
- Main category
- goods
- CPV classifications
- 33600000
- Contract locations
- UK
Award criteria
Criteria the buyer will use to evaluate bids.
| Name | Description | Type | Weighting |
|---|---|---|---|
| Ease of Use | 10% | quality | — |
| Security of Supply | 15% | quality | — |
| — | 75% | price | — |
Submission & procedure
- Procedure
- Open procedure
Award details· 33 awards
Awarded supplier(s), contract period and value as published in the award notice.
Awarded value
—
Award date
—
Contract start
—
Contract end
—
Lots · 23 total
Divisions of the contract. Each lot can be awarded separately.
| Lot | Title | Est. value | Status |
|---|---|---|---|
| 1 | CM/PHS/22/5661/01 Standard Half-life Recombinant Factor VIII | £1 | cancelled |
| 2 | CM/PHS/22/5661/02 Enhanced Half-life Recombinant Factor VIII | £1 | cancelled |
| 3 | CM/PHS/22/5661/03 Emicizumab | £1 | cancelled |
| 4 | CM/PHS/22/5661/04 eftrenonacog alfa (rFIX EHL) | £1 | cancelled |
| 5 | CM/PHS/22/5661/05 albutrepenonacog alfa (rFIX EHL) | £1 | cancelled |
Award 1· 1 supplier
Awarded —
Award 2· 1 supplier
Awarded —
Award 3· 1 supplier
Awarded —
Award 4· 1 supplier
Awarded —
Award 5· 1 supplier
Awarded —
Award 6· 1 supplier
Awarded —
Award 7· 1 supplier
Awarded —
Award 8· 1 supplier
Awarded —
Award 9· 1 supplier
Awarded —
Award 10· 1 supplier
Awarded —
Award 11· 1 supplier
Awarded —
Award 12· 1 supplier
Awarded —
Award 13· 1 supplier
Awarded —
Award 14· 1 supplier
Awarded —
Award 15· 1 supplier
Awarded —
Award 16· 1 supplier
Awarded —
Award 17· 1 supplier
Awarded —
Award 18· 1 supplier
Awarded —
Award 19· 1 supplier
Awarded —
Award 20· 1 supplier
Awarded —
Award 21· 1 supplier
Awarded —
Award 22· 1 supplier
Awarded —
Award 23· 1 supplier
Awarded —
Award 24· 1 supplier
Awarded —
Award 25· 1 supplier
Awarded —
Award 26· 1 supplier
Awarded —
Award 27· 1 supplier
Awarded —
Award 28· 1 supplier
Awarded —
Award 29· 1 supplier
Awarded —
Award 30· 1 supplier
Awarded —
Award 31· 1 supplier
Awarded —
Award 32· 0 suppliers
Awarded —
Award 33· 0 suppliers
Awarded —
Total lots
23
Awarded
23
Estimated total
£23
Awarded total
—
CM/PHS/22/5661/01 Standard Half-life Recombinant Factor VIII
Start
30 Jun 2024
End
30 Apr 2027
Estimated
£1
CPV
CM/PHS/22/5661/02 Enhanced Half-life Recombinant Factor VIII
Start
30 Jun 2024
End
30 Apr 2027
Estimated
£1
CPV
CM/PHS/22/5661/03 Emicizumab
Start
30 Jun 2024
End
30 Apr 2027
Estimated
£1
CPV
CM/PHS/22/5661/04 eftrenonacog alfa (rFIX EHL)
Start
30 Jun 2024
End
30 Apr 2027
Estimated
£1
CPV
CM/PHS/22/5661/05 albutrepenonacog alfa (rFIX EHL)
Start
30 Jun 2024
End
30 Apr 2027
Estimated
£1
CPV
CM/PHS/22/5661/06 nonacog beta pegol (rFIX EHL)
Start
30 Jun 2024
End
30 Apr 2027
Estimated
£1
CPV
CM/PHS/22/5661/07 rFIX - Standard Half Life
Start
30 Jun 2024
End
30 Apr 2027
Estimated
£1
CPV
CM/PHS/22/5661/08 Recombinant Factor VII
Start
30 Jun 2024
End
30 Apr 2027
Estimated
£1
CPV
CM/PHS/22/5661/09 Porcine Factor VIII - susoctocog alfa
Start
30 Jun 2024
End
30 Apr 2027
Estimated
£1
CPV
CM/PHS/22/5661/10 Factor VIII Inhibitor Bypassing Fraction
Start
30 Jun 2024
End
30 Apr 2027
Estimated
£1
CPV
CM/PHS/22/5661/11 Factor IX - High Purity Factor IX
Start
30 Jun 2024
End
30 Apr 2027
Estimated
£1
CPV
CM/PHS/22/5661/12 Factor X
Start
30 Jun 2024
End
30 Apr 2027
Estimated
£1
CPV
CM/PHS/22/5661/13 Factor XIII - Plasma Derived
Start
30 Jun 2024
End
30 Apr 2027
Estimated
£1
CPV
CM/PHS/22/5661/14 Factor XIII - Recombinant
Start
30 Jun 2024
End
30 Apr 2027
Estimated
£1
CPV
CM/PHS/22/5661/15 Von willebrands factor / Factor VIII
Start
30 Jun 2024
End
30 Apr 2027
Estimated
£1
CPV
CM/PHS/22/5661/16 Von willebrands factor - Plasma Derived
Start
30 Jun 2024
End
30 Apr 2027
Estimated
£1
CPV
CM/PHS/22/5661/17 Von willebrands factor - Recombinant
Start
30 Jun 2024
End
30 Apr 2027
Estimated
£1
CPV
CM/PHS/22/5661/18 Fibrinogen Concentrate
Start
30 Jun 2024
End
30 Apr 2027
Estimated
£1
CPV
CM/PHS/22/5661/19 Prothrombin Complex dried
Start
30 Jun 2024
End
30 Apr 2027
Estimated
£1
CPV
CM/PHS/22/5661/20 Protein C Concentrate
Start
30 Jun 2024
End
30 Apr 2027
Estimated
£1
CPV
CM/PHS/22/5661/21 Fresh Frozen Plasma (all blood groups)
Start
30 Jun 2024
End
30 Apr 2027
Estimated
£1
CPV
CM/PHS/22/5661/22 Freeze Dried Plasma
Start
30 Jun 2024
End
30 Apr 2027
Estimated
£1
CPV
CM/PHS/22/5661/23 Caplacizumab
Start
30 Jun 2024
End
30 Apr 2027
Estimated
£1
CPV
Other contracts from NHS England
Full notice and award history for this contracting authority is on the buyer profile.
Other contracts awarded to Pfizer Ltd· 10
Cross-buyer view of this supplier's public-sector wins.
| Title | Type | Value | Published |
|---|---|---|---|
| NHS Branded Medicines - Tranche B - London & South of England - 1 September 2026 | contract | — | 09 Jun 2026 |
| NHS National Branded Interim - 1 June 2026 | contract | — | 16 Apr 2026 |
| Generic Drugs – Injections/Infusions 2 | contract | — | 03 Mar 2026 |
| NHS National Generic Pharmaceuticals - Wave 15c | contract | — | 14 Jan 2026 |
| Family Planning Requisites | contract | — | 09 Dec 2025 |
| NHS National Proprietary Pharmaceuticals - Low Molecular Weight Heparins and Fondaparinux Products | contract | — | 28 Nov 2025 |
| NHS National Framework for Generics Housekeeping | contract | — | 11 Nov 2025 |
| NHS National Framework for Transition products (Axitinib and Eltrombopag) | contract | — | 30 Jul 2025 |
| NHS Branded Medicines Tranche B - MAE & NOFE - 1 September 2025 | contract | £47.0m | 29 Jul 2025 |
| NHS Branded Medicines Tranche A - London & SOFE & Adult Influenza National | contract | £9.4m | 24 Jul 2025 |